Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin Ethylsuccinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.88 |
| ▸ | HTR1A | P08908 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | ALB | P02768 | 1/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin Ethylsuccinate SCHEMBL537373 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL7866739 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL5082211 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL9807840 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL15665988 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL10673952 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL9118779 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL10382844 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL7750959 | 0.99 | CYP3A4 (0.98) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL7755531 | 0.98 | CYP3A4 (0.97) | CYP3A4SLCO1B3SLCO1B1USP2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 62166 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228841-A1 | COMPOSITIONS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | APTORUM THERAPEUTICS LTD (HK) | 2025-07-17 | — | — | US | claimed |
| CN-114641296-B | Preparation of an Ananamycin Liposome precursor lyophilized | 德州大学系统董事会 | 2025-05-27 | — | — | CN | claimed |
| US-12285471-B2 | Methods for treating pulmonary disease using inter-alpha inhibitor proteins | PROTHERA BIOLOGICS, INC. (US) | 2025-04-29 | — | — | US | claimed |
| CN-114444363-B | Method, device and equipment for calculating response of high-precision receiver at any position | 中南大学 | 2024-11-19 | — | — | CN | claimed |
| CN-118873548-A | Anti-liver cancer cell preparation and application thereof | 新乡医学院 | 2024-11-01 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118510533-A | Cancer diagnostic method using ephrin B2 expression | 血管基因治疗公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118389556-A | Perforin preparation method and application thereof | 复旦大学附属中山医院 | 2024-07-26 | — | — | CN | claimed |
| EP-3464579-B1 | COMPOSITIONS COMPRISING POLYPEPTIDES HAVING GALACTANASE ACTIVITY AND POLYPEPTIDES HAVING BETA-GALACTOSIDASE ACTIVITY | NOVOZYMES AS (DK) | 2024-07-17 | — | — | EP | claimed |
| EP-3925601-B1 | GASTRO-RESISTANT FORMULATION CONTAINING POSACONAZOLE AND A POLYMERIC PRECIPITATION INHIBITOR | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2024-07-17 | — | — | EP | claimed |
| EP-0005238-A2 | Floor covering for indoor or outdoor sporting and playing areas | Schmidt, Bernard L. (US) | 1979-11-14 | — | — | EP | claimed |
| EP-0004578-A1 | Pellets containing styrene polymer and aluminium hydroxide, and process for preparing flame-retarding styrene polymer foams | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-17 | — | — | EP | claimed |
| EP-0004587-A2 | Polyvinyl alcohol pellets containing a plasticizer, and method for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-17 | — | — | EP | claimed |
| EP-0003752-A1 | Process for preparing molecular-sieve-containing grains having good mechanical solidity, the grains manufactured by this process and their use | Kali-Chemie Aktiengesellschaft (DE) | 1979-09-05 | — | — | EP | claimed |
| WO-1979000606-A1 | PROCESS FOR OBTAINING ALUMINIUM BY ELECTROLYSIS IN A MELTED BATH | VAW VER ALUMINIUM WERKE AG (DE) | 1979-08-23 | — | — | WO | claimed |
| EP-0003598-A1 | Process for the production of aluminium by electrolysis of fused salts | VEREINIGTE ALUMINIUM-WERKE AKTIENGESELLSCHAFT (DE) | 1979-08-22 | — | — | EP | claimed |
| EP-0001766-A2 | Method for improving the processing qualities of powdery polyolefins | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-05-16 | — | — | EP | claimed |
| WO-1979000132-A1 | PROCESS AND DEVICE FOR THE GRANULATION OF MOLTEN MATERIALS | SVENSKT STAL AB (SE) | 1979-03-22 | — | — | WO | claimed |
| EP-0000357-A1 | Process for the preparation of cross-linkable ethylene polymer mouldings and their use as electrical insulating materials | BASF Aktiengesellschaft (DE) | 1979-01-24 | — | — | EP | claimed |
| US-4076804-A | Erythromycin therapy | ABBOTT LABORATORIES (US) | 1978-02-28 | — | — | US | claimed |